HK Inno.N speeds up clinical research on its NSCLC candidate

By Nho, Byung Chul | translator Kim, Jung-Ju

24.03.27 09:27:33

가나다라 0

Presents results on its EGFR-mutated NSCLC drug at AACR 2024

Plans to complete nonclinical studies and apply for a Phase I IND within the year

On the 27th, HK inno.N announced that it will present the non-clinical trial results of its next-generation allosteric EGFR-tyrosine kinase inhibitor ("EGFR-TKI") candidate through a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 from April 5 to 10 in the United States.

e AACR is one of the world's three most prestigious cancer conferences along with the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO), and annually attracts a large number of experts from around the world to share their latest cancer research findings.

At the conference, HK Inno.N will present the results of its nonclinical s

Nho, Byung Chul(sasiman@dailypharm.com)

If you want to see the full article, please JOIN US (click)